EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biohaven's enterprise value is $3,098.05 Mil.
Biohaven's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Biohaven's EV-to-Revenue for today is .
The historical rank and industry rank for Biohaven's EV-to-Revenue or its related term are showing as below:
BHVN's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.58 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-04-19), Biohaven's stock price is $38.99.
Biohaven's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Biohaven's PS Ratio for today is .
Biohaven EV-to-Revenue Historical Data
The historical data trend for Biohaven's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biohaven Annual Data
Trend
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
-
-
-
-
Biohaven Quarterly Data
Dec20
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
-
-
-
-
-
Competitive Comparison
For the Biotechnology subindustry, Biohaven's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohaven EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Biohaven's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Biohaven's EV-to-Revenue falls into.
Biohaven's current Enterprise Value is $3,098.05 Mil.
Biohaven's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohaven's share price for today is $38.99.
Biohaven's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohaven EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Biohaven's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BHVN has been successfully added to your 